Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for abrdn Life Sciences Investors's Intrinsic Value: Projected FCF or its related term are showing as below:
HQL'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.05 Med: 1.1 Max: 1.42
Current: 1.42
During the past 9 years, the highest Price-to-Intrinsic-Value-Projected-FCF of abrdn Life Sciences Investors was 1.42. The lowest was 1.05. And the median was 1.10.
HQL's Price-to-Projected-FCF is ranked worse than 78.93% of 1215
companies
in the Asset Management industry
Industry Median: 0.91
vs HQL: 1.42
abrdn Life Sciences Investors (NYSE:HQL) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
abrdn Life Sciences Investors's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
20.96
/
14.800046699028
=
1.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Intrinsic Value: Projected FCF Related Terms
abrdn Life Sciences Investors Intrinsic Value: Projected FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Intrinsic Value: Projected FCF Chart
HQL vs MUJ, ACP, NKX: Intrinsic Value: Projected FCF Comparison
For the Asset Management subindustry, abrdn Life Sciences Investors's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors Price-to-Projected-FCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's Price-to-Projected-FCF falls into.
abrdn Life Sciences Investors Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $14.80 mean?
abrdn Life Sciences Investors (HQL) has a Intrinsic Value: Projected FCF of $14.80 as of Aug. 31, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #959 out of 1215 companies in the Asset Management industry, placing it in the top 78.9%.
Is abrdn Life Sciences Investors' Intrinsic Value: Projected FCF too high?
abrdn Life Sciences Investors' current Intrinsic Value: Projected FCF is $14.80. The Asset Management industry median Intrinsic Value: Projected FCF is 0.91. abrdn Life Sciences Investors' value of $14.80 is 1526.4% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #959 out of 1215 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Intrinsic Value: Projected FCF compare to MUJ and ACP?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #959 out of 1215 companies for Intrinsic Value: Projected FCF. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 0.91. abrdn Life Sciences Investors' value of $14.80 is 1526.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for an Asset Management company?
The median Intrinsic Value: Projected FCF among Asset Management companies is 0.91, based on 1,215 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current Intrinsic Value: Projected FCF of $14.80 is 1526.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median Intrinsic Value: Projected FCF is 0.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current Intrinsic Value: Projected FCF is $14.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $20.96 — trading 66.2% below its estimated fair value. The current Intrinsic Value: Projected FCF is $14.80 and 1526.4% above the Asset Management industry median of 0.91. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Intrinsic Value: Projected FCF is $14.80 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $20.96 is trading 66.2% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
Intrinsic Value: Projected FCF: $14.80
GF Value™: $62.01 vs. price of $20.96 (66.2% below fair value)
Industry Position: 1526.4% above the Asset Management median (#959 of 1215)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
